Retrospective Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Aug 14, 2019; 25(30): 4235-4245
Published online Aug 14, 2019. doi: 10.3748/wjg.v25.i30.4235
Table 1 Characteristics of mild Crohn’s patients at diagnosis, n (%)
VariablesMild case (n = 29)Moderate or severe case (n = 58)P value
Age at diagnosis, yr10.0 (4.2)11.6 (3.3)0.06
Male %15 (51.7)29 (52.7)0.93
Paris Location at diagnosis
Lower 1/3 of ileum +/- base of cecum6 (20.7)7 (12.1)0.29
Colon only9 (31.0)7 (12.1)0.03
Ileum and colon13 (44.8)41 (70.7)0.02
Upper GI proximal to ligament of treitz7 (24.1)25 (43.1)0.08
Distal to ligament of treitz to proximal ileum1 (3.5)2 (3.5)1.00
Disease behavior at diagnosis
Inflammatory (non-stricturing, non-penetrating)28 (96.6)51 (87.9)0.19
Stricturing0 (0)3 (5.2)0.21
Penetrating0 (0)1 (1.7)0.48
Perianal3 (10.3)12 (20.7)0.23
Table 2 Outcome of mild disease patients after the first 2 years of study entry
n (%)
Starting immunomodulator8 (27.6)
Starting biologic0
Starting immunomodulator and biologic0
Surgery0
Continued on minimal therapy21 (72.4)
Table 3 Predictors of escalation to immunomodulators among mild Crohn’s patients
Univariate
P value
Hazard ratio (95%CI)
Age at diagnosis1.24 (0.97-1.59)0.09
Gender (female vs male)0.67 (0.15-3.00)0.60
Paris location at diagnosis
Lower 1/3 of ileum +/- base of cecum1.29 (0.30-5.66)0.73
Colon only0.96 (0.19-4.99)0.96
Ileum and colon0.50 (0.10-2.53)0.40
Upper GI proximal to Ligament of Treitz1.00 (0.19-5.17)1.00
Distal to Ligament of Treitz to proximal ileum5.46 (0.61-49.27)0.13
Any steroids in the first 2 yr1.26 (0.30-5.35)0.75
Any steroids after the first 2 yr12.1 (1.4-102.7)0.02
Complications5.6 (1.3-24.9)0.02
Table 4 Detailed outcomes of 29 patients on no immunosuppressive therapy for mild Crohn’s disease
Year (age) of diagnosisDuration of follow-up after initial 2 yr of treatment (mo)Followup colonoscopy histology findingsMedicationsOutcome/ complications
2002 (10 yr)1112007-normal colonoscopy5-ASA (Asacol), prednisoneEscalation to 6MP(age 20) Surgery for ileal stricture (age 22)
2004 (12 yr)492009-Noncaseating granulomas in TI and throughout colon.5-ASA (Pentasa, Lialda)Stayed on ASA, no escalation
2001 (9 yr)32Not done5-ASA, prednisoneStayed on ASA, no prednisone after induction, no escalation
2002 (10 yr)1312009- chronic active ileitis with ulceration5-ASA (Pentasa, Lialda)2015-escalation to mercaptopurine, then adalimumab
2003 (10 yr)662010-severely active ileitis5-ASA (Pentasa), 3 courses of prednisone over 3 years2012-began mercaptopurine
2005 (13 yr)15Not done5-ASA (Asacol)Ileal phlegmon, treated with antibiotics and subsequent mercaptopurine
2010 (16 yr)432014-nonnecrotizing granuloma throughout the colon5-ASA (Asacol)Stayed on ASA, no escalation.
2010 (16 yr)1Not done5-ASA (Asacol), hydrocortisoneStayed on ASA, no steroid after initial induction
2008 (14 yr)632010-mild active ileitis colitis in ascending and sigmoid colon5-ASA (Asacol), metronidazoleStayed on ASA, no escalation
2012 (17 yr)72014-nonnecrotizing granulomas in left colon5-ASA (Pentasa)Escalation to mercaptopurine, then adalimumab
2008 (14 yr)652012-normal ileum, chronic active colitis 2016-normal colonoscopy5-ASA (Pentasa), budesonideNo escalation
2008 (13 yr)472014-mild active colitis, in ascending, granuloma in ileum5-ASA (Pentasa), metronidazole6MP initiated
2007 (12 yr)712016-Inactive colitis at IC valve5-ASA (Asacol)Ileal stricture in 2016, no surgery yet
2008 (13 yr)212009-active colitis in cecum, inactive in remainder of colon5-ASA (Pentasa, Lialda)Discontinued all therapy, never hospitalized
2005 (10 yr)14None prior to escalation5-ASA (Pentasa), metronidazole6MP, then infliximab
2010 (15 yr)6None5-ASA (Pentasa), prednisone inductionNo escalation
2005 (9 yr)852013-focal mild ileitis5-ASA (Pentasa), metronidazoleNo escalation
2000 (4 yr)1Not doneSulfasalazine, flagylBegun infliximab for colonic and perianal disease
2002 (12 yr)382012-normal colonoscopy5-ASA (mesalamine), prednisoneNo escalation
2006 (9 yr)872016-chronic active colitis, non- necrotizing granuloma in transverse colon5-ASA (Pentasa), two courses of steroids in first two yearsNo escalation
2002 (4 yr)1362010-mild active colitisSulfasalazine, budesonideNo escalation
2001 (3 yr)100Not doneSulfasalazine, budesonideNo escalation
2003 (5 yr)1182012-focal moderately active colitisSulfasalazine, prednisoneNo escalation
2009 (10 yr)412014-focal acute inflammation5ASA (Asacol), BudesonideNo escalation
2005 (7 yr)992014-mildly active colitisPentasaNo escalation
2007 (6 yr)972013- chronic inactive colitisPentasa, SulfasalazineNo escalation
2012 (10 yr)162013-mild active colitis with granulomataAsacol, prednisone inductionNo escalation
2008 (3 yr)54Not doneSulfasalazine, probioticsNo escalation
2010 (3 yr)112012-chronic moderately active colitisSulfasalazine, prednisone inductionNo escalation